Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Follow-Up Questions
Bicycle Therapeutics PLC의 CEO는 누구입니까?
Dr. Kevin Lee은 2015부터 회사에 합류한 Bicycle Therapeutics PLC의 Chief Executive Officer입니다.
BCYC 주식의 가격 성능은 어떻습니까?
BCYC의 현재 가격은 $7.01이며, 전 거래일에 decreased 2.09% 하였습니다.
Bicycle Therapeutics PLC의 주요 사업 주제나 업종은 무엇입니까?
Bicycle Therapeutics PLC은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Bicycle Therapeutics PLC의 시가총액은 얼마입니까?
Bicycle Therapeutics PLC의 현재 시가총액은 $485.8M입니다
Bicycle Therapeutics PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 14명의 분석가가 Bicycle Therapeutics PLC에 대한 분석 평가를 실시했으며, 이는 6명의 강력한 매수, 10명의 매수, 4명의 보유, 0명의 매도, 그리고 6명의 강력한 매도를 포함합니다
